View Cart  

BMS Resubmits Eliquis NDA, Gets Mid-March PDUFA Date

A A
Bristol-Myers Squibb (BMS) and Pfizer have resubmitted their NDA for Eliquis to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).

To View This Article:

Login

Subscribe To Drug Industry Daily